Leaderboards/BRAF

BRAF

Last updated May 19, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
René Adam
Université Paris-Saclay
510 cit.
2
Scott Kopetz
The University of Texas MD Anderson Cancer Center
489 cit.
3
Georgina V. Long
The University of Sydney
261 cit.
4
Dyke Ferber
Heidelberg University
233 cit.
5
Yash Chhabra
Fox Chase Cancer Center
141 cit.
6
Margherita Ambrosini
Fondazione IRCCS Istituto Nazionale dei Tumori
140 cit.
7
Jessica S.W. Borgers
The Netherlands Cancer Institute
123 cit.
8
Pingmei Huang
Chinese University of Hong Kong
120 cit.
9
Kanwal Raghav
The University of Texas MD Anderson Cancer Center
119 cit.
10
Claus Garbe
Unknown
115 cit.

Rising Stars Papers

1
Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial
The Lancet|2024
148 cit.
2
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
Nature Medicine|2025
91 cit.
3
Development and validation of an autonomous artificial intelligence agent for clinical decision-making in oncology
Nature Cancer|2025
92 cit.
4
Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial
Nature Medicine|2024
70 cit.
5
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
Journal of Clinical Oncology|2024
48 cit.
6
Sex-dependent effects in the aged melanoma tumor microenvironment influence invasion and resistance to targeted therapy
Cell|2024
46 cit.
7
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer
Annals of Oncology|2024
69 cit.
8
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
Nature Medicine|2025
40 cit.
9
Peptostreptococcus stomatis promotes colonic tumorigenesis and receptor tyrosine kinase inhibitor resistance by activating ERBB2-MAPK
Cell Host & Microbe|2024
47 cit.
10
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
The Lancet Oncology|2024
118 cit.

Rising Stars Reagents

Coming soon

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Maria E. Cabanillas
The University of Texas MD Anderson Cancer Center
887 cit.
2
Karsten Nysom
Copenhagen University Hospital
169 cit.
3
Jong Bae Park
National Cancer Center
128 cit.
4
Bruce E. Johnson
Dana-Farber Cancer Institute
111 cit.
5
Georgina V. Long
The University of Sydney
108 cit.
6
Darren Hargrave
Royal Children's Hospital
85 cit.
7
Giuseppe Palmieri
University of Sassari
83 cit.
8
Francesco Spagnolo
Ospedale Policlinico San Martino
67 cit.
9
Volker Heinemann
German Cancer Research Center
66 cit.
10
Margit Hagel
Sage Therapeutics (United States)
65 cit.

Emerging Leaders Papers

1
Thyroid Cancer
JAMA|2024
568 cit.
2
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
Nature Medicine|2023
169 cit.
3
Integrated proteogenomic characterization of glioblastoma evolution
Cancer Cell|2024
85 cit.
4
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Non–Small-Cell Lung Cancer
Journal of Clinical Oncology|2023
111 cit.
5
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma
Journal of Clinical Oncology|2023
108 cit.
6
Dabrafenib plus Trametinib in Pediatric Glioma with <i>BRAF</i> V600 Mutations
New England Journal of Medicine|2023
255 cit.
7
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
Nature Communications|2024
83 cit.
8
The treatment of advanced melanoma: Current approaches and new challenges
Critical Reviews in Oncology/Hematology|2024
133 cit.
9
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of <i>BRAF</i><sup>V600E</sup>-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study
Journal of Clinical Oncology|2023
66 cit.
10
The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers
Cancer Discovery|2024
43 cit.

Emerging Leaders Reagents

Coming soon

All-Time Leaders

The canon

All-Time Leaders Researchers

1
P. Andrew Futreal
Wellcome Sanger Institute
32k cit.
2
Paul B. Chapman
Memorial Sloan Kettering Cancer Center
12.4k cit.
3
Arul M. Chinnaiyan
Howard Hughes Medical Institute
10.9k cit.
4
Solange Peters
University Hospital of Lausanne
9.8k cit.
5
Feng Zhang
McGovern Institute for Brain Research
8.8k cit.
6
X. Shirley Liu
Dana-Farber Cancer Institute
8.3k cit.
7
James Larkin
Royal Marsden NHS Foundation Trust
8k cit.
8
Lynda Chin
Broad Institute
7.8k cit.
9
Grant A. McArthur
Peter MacCallum Cancer Centre
7.7k cit.
10
Boris C. Bastian
UCSF Helen Diller Family Comprehensive Cancer Center
7.5k cit.

All-Time Leaders Papers

1
Mutations of the BRAF gene in human cancer
Nature|2002
10.7k cit.
2
The Immune Landscape of Cancer
Immunity|2018
6.2k cit.
3
Integrative Clinical Genomics of Advanced Prostate Cancer
Cell|2015
3.6k cit.
4
Genomic Classification of Cutaneous Melanoma
Cell|2015
3.2k cit.
5
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Cell|2014
3.1k cit.
6
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
The Lancet|2012
3k cit.
7
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Nature|2014
2.9k cit.
8
MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens
Genome biology|2014
2.8k cit.
9
A Landscape of Driver Mutations in Melanoma
Cell|2012
2.6k cit.
10
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
New England Journal of Medicine|2011
7.7k cit.

All-Time Leaders Reagents

Coming soon

Indexing BRAF Reagents

Citation data for reagents in this field is currently compiling.